Breast cancer, HER2-positive - historical
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main HER2+ breast cancer page for current regimens.
11 regimens on this page
13 variants on this page
|
Metastatic disease, first-line chemotherapy
Note: in many of these regimens, patients were allowed to have received (neo)adjuvant chemotherapy and hormonal therapy (when applicable). These are first-line regimens in the metastatic setting, with a few being specifically for the locally advanced but unresectable setting.
AC
| back to top |
AC: Adriamycin (Doxorubicin) & Cyclophosphamide
Regimen
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Slamon et al. 2001 | Phase III (C) | ACH | Seems to have inferior OS |
Note: patients in Slamon et al. 2001 had not previously received adjuvant (postoperative) therapy with an anthracycline.
Chemotherapy
- Doxorubicin (Adriamycin) 60 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 600 mg/m2 IV once on day 1
21-day cycles
References
- Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. link to original article PubMed
Docetaxel monotherapy
| back to top |
D: Docetaxel
T: Taxotere (Docetaxel)
Regimen
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Marty et al. 2005 (M77001) | Phase III (C) | Docetaxel & Trastuzumab | Seems to have inferior OS |
Chemotherapy
- Docetaxel (Taxotere) 100 mg/m2 IV over 60 minutes once on day 1
21-day cycles
References
- M77001: Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005 Jul 1;23(19):4265-74. Epub 2005 May 23. link to original article contains verified protocol PubMed
EC
| back to top |
EC: Epirubicin & Cyclophosphamide
Regimen
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Slamon et al. 2001 | Phase III (C) | ECH | Seems to have inferior OS |
Chemotherapy
- Epirubicin (Ellence) 75 mg/m2 IV once on day 1
- Cyclophosphamide (Cytoxan) 600 mg/m2 IV once on day 1
21-day cycle for up to 6 to 8 cycles
References
- Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. link to original article PubMed
Paclitaxel monotherapy, q3wk
| back to top |
Regimen
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Slamon et al. 2001 | Phase III (C) | TH | Seems to have inferior OS |
Note: patients in EGF30001 were NOT required to be HER2-positive.
Chemotherapy
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
21-day cycles
References
- Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. link to original article PubMed